Notable negative changes in fundamentals have recently occurred for Avanos Medical Inc (NYSE: AVNS): the consensus estimate for December, 2023 decreased significantly, significant quarterly earnings deceleration occurred, and the consensus estimate for December, 2024 decreased significantly.
Avanos Medical Inc (NYSE: AVNS) has recently experienced significant negative changes in investment behavior: its shorter term price trend turned down.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
AVNS is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Avanos Medical has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Avanos Medical has a good Appreciation Score of 73 but a poor Power Rating of 16, and the Low Neutral Value Trend Rating results.
Recent Price Action
Avanos Medical Inc (NYSE: AVNS) stock rose modestly by 0.8% on 1/12/24. The stock closed at $19.50. NORMAL trading volume accompanied the advance. The stock has been weak relative to the market over the last nine months but has risen 8.5% during the last week.
Be the first to comment